Unlock the potential of neoantigen-driven immunotherapy


myNEO focuses on research, development, and optimisation of the clinical exploitability of personalised cancer immunotherapy.

It is myNEO’s mission to enable improved neoantigen-directed immunotherapy by integrating three important pillars of successful therapy. myNEO’s primary focus is to tackle the challenge of identifying, in a quick but accurate way, the neoantigen targets that determine the success of each immunotherapy. These – often personalised – neoantigens are obtained by interpreting tumour samples with data-driven neural networks trained on gathered biological datasets. But personalisation can be pushed even further, by immune typing of the tumour micro-environment to ensure that the best (combination) therapy is selected. Lastly, myNEO enables efficient monitoring of treatment response and disease progression using personalised biomarkers.

 

 

 

Neoantigen prediction


The myNEO technology platform focuses on identifying, exploring and validating unusual alterations and their immunogenic impact. In a personalised manner, the sequencing data of tumour cells (biopsy) and healthy cells (blood) are compared, and tumour-specific alterations leading to peptides present on the tumour surface are annotated. Since these antigens are absent from healthy cells, they can have important immunogenic implications, and are fit for use in therapeutic or prognostic applications. The bioinformatic platform is incorporated in a comprehensive end-to-end flow ranging from sample processing to vaccine construct design.

Pipeline improvement


Prioritising on continuous improvement of the neoantigen prediction pipeline, by incorporating new algorithms based on in-house research and our academic/industrial collaborations. Both private and public validated antigen sets are used to train, test, and optimise the prediction platform.

Cold tumours


Discovering a broad set of neoantigens to enable identification of valuable targets in cold tumours where other immunotherapies are not working adequately. Proprietary algorithms combined with enhanced patient datasets allow for detection of novel antigen types caused by unusual tumour alterations. Both the MHC-I and MHC-II epitopes arising from these tumour-mutational processes are deemed more valuable as targets.

Validated prediction


Lowering the number of falsely identified neoantigens. Important screening steps take place to validate the results of the bioinformatics platform. These involve tandem mass spectrometry analysis of the HLA ligandome and various immunogenicity assays. To cope with the limitation of large biopsy sample requirements for mass spec analysis, a cross-patient employable deep-learning algorithm predicts which antigens are most likely to be presented on the patient tumour cells. 

Smart vaccine design


Assisting partners in designing the optimal vaccination construct containing the selected targets. Multi-epitope constructs containing a carefully selected combination of MHC-I and MHC-II presented epitopes ensure induction of an enhanced immune response against the tumour antigens.

Clinical End-2-End flow


Integrating the platform in an end-to-end solution for clinical use, including sample fixation and preparation, state-of-the-art sequencing, tumour microenvironment screening, and immunogenicity testing. Key to the development of the myNEO sample flow has been the condition of clinical-grade platform use, allowing the personalised therapy to reach the patient in time and in a cost-effective manner. 

Set-up partnerships


Setting up clinical and research collaborations due to our strong belief in the phrase ‘together we achieve more’. We acknowledge that identifying the correct target in a patient sample is only part of the end puzzle, and there are several other critical success factors when developing therapeutic cancer vaccines. 

Trusted by